Cent Eur J Public Health 2009, 17(3):133-138 | DOI: 10.21101/cejph.b0016

The "Five Risks Algorithm": an Easy Tool for Cardiovascular Risk Estimation

Dirk Devroey, Jan Vandevoorde
Department of General Practice, Vrije Universiteit Brussel, Brussels, Belgium

The aim of this study is to provide an easy tool to identify patients with a high cardiovascular risk, especially those qualifying for lipid-lowering treatment. The decision to treat with lipid-lowering drugs was assessed with five new risk algorithms. The Five Risk algorithm (5R) takes into account male gender, high systolic blood pressure, high total cholesterol, smoking and high blood sugar as independent risk factors. Patients with three independent risk factors qualify for lipid-lowering treatment. Compared to the Framingham Risk Score, the 5R has a Kappa coefficient of 0.62. Compared to the SCORE, the Six Risk algorithm (6RDF) has a Kappa coefficient of 0.70. The 6RDF uses only four independent risk factors (male gender, high systolic blood pressure, high total cholesterol and smoking) but having diabetes or a family history of premature coronary heart disease are exclusion criteria for which treatment with lipid-lowering drugs is always indicated.

Keywords: cardiovascular risk, cardiovascular diseases, primary prevention, cholesterol, blood pressure, diabetes

Received: November 4, 2008; Revised: April 30, 2009; Accepted: April 30, 2009; Published: September 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Devroey D, Vandevoorde J. The "Five Risks Algorithm": an Easy Tool for Cardiovascular Risk Estimation. Cent Eur J Public Health. 2009;17(3):133-138. doi: 10.21101/cejph.b0016. PubMed PMID: 20020602.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Menotti A, Puddu PE, Lanti M. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J. 2000 Mar;21(5):365-70. Go to original source... Go to PubMed...
    2. Thomsen TF, McGee D, Davidsen M, Jørgensen T. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol. 2002 Aug;31(4):817-22. Go to original source...
    3. Hense HW, Schulte H, Löwel H, Assmann G, Keil U. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany-results from the MONICAAugsburg and the PROCAM cohorts. Eur Heart J. 2003 May;24(10):937-45. Go to original source... Go to PubMed...
    4. Executive summary of the Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486-97. Go to original source... Go to PubMed...
    5. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, de Backer G, et al; SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003 Jun;24(11):987-1003. Go to original source...
    6. The assessment and management of cardiovascular risk [monograph on the Internet]. Wellington: New Zealand Guidelines Group; 2003 [cited 2008 Apr]. Available from: http://www.nzgg.org.nz/guidelines/0035/CVD_Risk_Full.pdf.
    7. Ramsay LE, Haq IU, Jackson PR, Yeo WW, Pickin DM, Payne JN. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet. 1996Aug 10;348(9024):387 Go to original source...
    8. Erratum in: Lancet. 1996 Nov 2;348(9036):1251.
    9. Neuhauser HK, Ellert U, Kurth BM. A comparison of Framingham and SCORE-based cardiovascular risk estimates in participants of the German National Health Interview and Examination Survey 1998. Eur J Cardiovasc Prev Rehabil. 2005 Oct;12(5):442-50. Go to original source... Go to PubMed...
    10. Denti L, Annoni V, Campana V, Salvagnini MA, Valenti G. The indication to statin therapy in primary prevention patients with dyslipidemia: implications for using national risk functions in the Italian population. Ital Heart J Suppl. 2004 Nov;5(11):868-75. (In Italian.)
    11. de Visser CL, Bilo HJ, Thomsen TF, Groenier KH, Meyboom-de Jong B. Prediction of coronary heart disease: a comparison between the Copenhagen risk score and the Framingham risk score applied to a Dutch population. J Intern Med. 2003 May;253(5):553-62. Go to original source... Go to PubMed...
    12. Devroey D, Kartounian J, Vandevoorde J, Betz W, Cogge N, de Man B, et al. Primary prevention of coronary heart disease in general practice: a cross sectional population study. Int J Clin Pract. 2004 Feb;58(2):130-8. Go to original source... Go to PubMed...
    13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 Jun;18(6):499-502. Go to original source...
    14. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977 Mar;33(1):159-74. Go to original source... Go to PubMed...
    15. De Muylder R, Lorant V, Paulus D, Nackers F, Jeanjean M, Boland B. Obstacles to cardiovascular prevention in general practice.Acta Cardiol. 2004 Apr;59(2):119-25. Go to original source... Go to PubMed...
    16. Van Steenkiste B, van der Weijden T, Stoffers HE, Grol R. Barriers to implementing cardiovascular risk tables in routine general practice. Scand J Prim Health Care. 2004 Mar;22(1):32-7. Go to original source...
    17. Thompson SG, Pocock SJ. The variability of serum cholesterol measurements: implications for screening and monitoring. J Clin Epidemiol. 1990;43(8):783-9. Go to original source...
    18. Sebastián-Gámbaro MA, Lirón-Hernández FJ, Fuentes-Arderiu X. Intraand inter-individual biological variability data bank. Eur J CIin Chem Clin Biochem. 1997 Nov;35(11):845-52.
    19. Reynolds TM, Twomey P, Wierzbicki AS. Accuracy of cardiovascular risk estimation for primary prevention in patients without diabetes. J Cardiovasc Risk. 2002 Aug;9(4):183-90. Go to original source...
    20. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007 Sep;14 Suppl 2:S1-113. Go to original source... Go to PubMed...
    21. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003 Sep;24(17):1601-10. Go to original source... Go to PubMed...
    22. Marrugat J, Subirana I, Comín E, Cabezas C, Vila J, Elosua R, et al; VERIFICA Investigators. Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA Study. J Epidemiol Community Health. 2007 Jan;61(1):40-7. Erratum in: J Epidemiol Community Health. 2007 Jul;61(7):655. Go to original source... Go to PubMed...
    23. Brindle PM, McConnachie A, Upton MN, Hart CL, Davey Smith G, Watt GC. The accuracy of the Framingham risk-score in different socioeconomic groups: a prospective study. Br J Gen Pract. 2005 Nov;55(520):838-45.
    24. Ulmer H, Kollerits B, Kelleher C, Diem G, Concin H. Predictive accuracy of the SCORE risk function for cardiovascular disease in clinical practice: a prospective evaluation of 44 649 Austrian men and women. Eur J Cardiovasc Prev Rehabil. 2005 Oct;12(5):433-41. Go to original source...
    25. VergnaudAC, Bertrais S, Galan P, Hercberg S, Czernichow S.Ten-year risk prediction in French men using the Framingham coronary score: results from the national SU.VI.MAX cohort. Prev Med. 2008 Jul;47(1):61-5. Go to original source... Go to PubMed...
    26. Mathes P. Cholesterol: blood levels or total risk as a guide to preventive treatment? Z Kardiol. 2004;93 Suppl 2:II16-20. (In German.)
    27. Yusuf S, Hawken S, Ôunpuu S, Dans T,AvezumA, Lanas F, et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004 Sep 11-17;364(9438):937-52. Go to original source... Go to PubMed...
    28. Yikona JI, Wallis EJ, Ramsay LE, Jackson PR. Coronary and cardiovascular risk estimation in uncomplicated mild hypertension. A comparison of risk assessment methods. J Hypertens. 2002 Nov;20(11):2173-82. Go to original source...
    29. Chi D, Nakano M, Yamamoto K. Milk and milk products consumption in relationship to serum lipid-levels: a community-based study of middle-aged and older population in Japan. Cent Eur J Public Health. 2004 Jun;12(2):84-7.
    30. Markoglou NCh, Hatzitolios AI, Savopoulos ChG, Ziakas AG, Koutsopoulos D, Metallidis S. Epidemiologic characteristics of hypertension in the civilians of Kosovo after the war. Cent Eur J Public Health 2005 Jun;13(2):61-5.

    Return to the content